AstraZeneca and Oxford University announce landmark agreement for COVID-19 vaccine
- Details
- Category: AstraZeneca
AstraZeneca and the University of Oxford announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine aimed at preventing COVID-19 infection from SARS-CoV-2.
The collaboration aims to bring to patients the potential vaccine known as ChAdOx1 nCoV-19, being developed by the Jenner Institute and Oxford Vaccine Group, at the University of Oxford.
Gilead announces results from Phase 3 trial of investigational antiviral remdesivir in patients with severe COVID-19
- Details
- Category: Gilead
Gilead Sciences, Inc. (Nasdaq: GILD) announced topline results from the open-label, Phase 3 SIMPLE trial evaluating 5-day and 10-day dosing durations of the investigational antiviral remdesivir in hospitalized patients with severe manifestations of COVID-19 disease. The study demonstrated that patients receiving a 10-day treatment course of remdesivir achieved similar improvement in clinical status compared with those taking a 5-day treatment course (Odds Ratio: 0.75 [95% CI 0.51 - 1.12] on Day 14).
Novartis announces plan to initiate clinical trial of canakinumab for patients with COVID-19 pneumonia
- Details
- Category: Novartis
Novartis today announced plans to initiate a Phase III clinical trial to study canakinumab in patients with COVID-19 pneumonia. The CAN-COVID trial will examine the efficacy of utilizing canakinumab, an interleukin (IL)-1β blocker, to treat a type of severe immune overreaction called cytokine release syndrome (CRS) in people with COVID-19 pneumonia.
Sanofi and Regeneron provide update on U.S. Phase 2/3 adaptive-designed trial in hospitalized COVID-19 patients
- Details
- Category: Sanofi
Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the preliminary results from the Phase 2 portion of an ongoing Phase 2/3 trial evaluating Kevzara® (sarilumab), an interleukin-6 (IL-6) receptor antibody, in hospitalized patients with "severe" or "critical" respiratory illness caused by COVID-19.
AstraZeneca and Saint Luke’s Mid America Heart Institute initiate Phase III DARE-19 trial with Farxiga in COVID-19 patients
- Details
- Category: AstraZeneca
AstraZeneca and Saint Luke's Mid America Heart Institute have initiated a randomised, global Phase III trial to assess the potential of Farxiga (dapagliflozin) as a treatment in patients hospitalised with COVID-19 who are at risk of developing serious complications, such as organ failure.
Bayer partners with Population Health Research Institute (PHRI) on global clinical research evaluating COVID-19 treatments
- Details
- Category: Bayer
Bayer announced today its Canadian organization Bayer Inc., Mississauga, Ontario, will partner with the Population Health Research Institute (PHRI) in launching a major clinical research program aimed at identifying potential treatments against COVID-19. The two studies will evaluate the safety and efficacy of different combination therapies including Bayer's chloroquine and interferon beta-1b.
Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
- Details
- Category: GlaxoSmithKline
Sanofi and GSK have signed a letter of intent to enter into a collaboration to develop an adjuvanted vaccine for COVID-19, using innovative technology from both companies, to help address the ongoing pandemic.
Sanofi will contribute its S-protein COVID-19 antigen, which is based on recombinant DNA technology. This technology has produced an exact genetic match to
More Pharma News ...
- Boehringer Ingelheim steps up effort with Global Support Program
- AstraZeneca initiates CALAVI clinical trial with Calquence against COVID-19
- Sanofi to donate 100 million doses of hydroxychloroquine across 50 countries
- Pfizer and BioNTech announce further details on collaboration to accelerate global COVID-19 vaccine development
- GSK and Vir Biotechnology enter collaboration to find coronavirus solutions
- Novartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish international compassionate use program
- Johnson & Johnson announces a lead vaccine candidate for COVID-19